EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative study on government subsidy models for competitive drug supply chains under centralized procurement policy

Yan Wen, Yan Wei, Lu Liu

Frontiers in Public Health · 2025

DOI: 10.3389/fpubh.2025.1542858 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Frontiers in Public Health, 2025. Verfasst von Yan Wen und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Business, Qingdao University, Qingdao, China. Hauptthemen laut MEDLINE: Economic Competition, Drugs, Generic, Drug Industry, Financing, Government. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As the generic drug market tends to be saturated, the structural transformation of generic drug companies is imminent, while the high investment and high-risk attributes of innovative drug research and development aggravate the transformation difficulties. Against the backdrop of drug centralized procurement policy, considering the effect of health insurance reimbursement and market competition ferocity, this study constructs a differential game model of a secondary drug supply chain comprising two competing drug companies and a single healthcare institution. In addition, this study comparatively analyzes the optimal equilibrium strategies and supply chain profit levels of drug research and development investment and healthcare service efforts under four government subsidy modes, further discussing them along with arithmetic examples. It is found that the government's subsidy behavior markedly influenced drug companies' investment in drug research and development and healthcare institution' service cost investment. Besides, different incentives for supply chain members' decision-making and profits were noted in different markets with different competition intensities. In the low-intensity competition market, the government's subsidies to innovative drug companies generate much higher social welfare than other modes. In the high-intensity competition market, the government subsidized healthcare institution can minimize the mutually exclusive effects of subsidies on the development of innovative and generic drug companies, and eventually drive the reform and development of the entire drug industry.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Economic CompetitionDrugs, GenericDrug IndustryFinancing, GovernmentHumans

Stichwörter der Autor:innen

centralized procurementdifferential gamedrug supply chaingovernment subsidiesinnovative drug

Substanzen

Drugs, Generic

Autor:innen und Institutionen

  • School of Business, Qingdao University, Qingdao, China.

Förderung

  • Natural Science Foundation of Shandong Province

Zitieren

APA

Wen, Y., Wei, Y., & Liu, L. (2025). Comparative study on government subsidy models for competitive drug supply chains under centralized procurement policy. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2025.1542858

Vancouver

Wen Y, Wei Y, Liu L. Comparative study on government subsidy models for competitive drug supply chains under centralized procurement policy. Frontiers in Public Health. 2025. doi:10.3389/fpubh.2025.1542858

BibTeX
@article{Wen2025,
  author = {Wen, Yan and Wei, Yan and Liu, Lu},
  title = {Comparative study on government subsidy models for competitive drug supply chains under centralized procurement policy},
  journal = {Frontiers in Public Health},
  year = {2025},
  doi = {10.3389/fpubh.2025.1542858}
}
Kostenlos starten →